Combined Pulmonary Tuberculosis with Pulmonary and Pleural Cryptococcosis in a Patient Receiving Ruxolitinib Therapy
Akarawut Kasemchaiyanun,1 Thitiporn Suwatanapongched,2 Pimpin Incharoen,3 Sirithep Plumworasawat,3 Jackrapong Bruminhent4 1Division of Pulmonary and Critical Care Medicine, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 2Division of Diagnosti...
Main Authors: | Kasemchaiyanun A, Suwatanapongched T, Incharoen P, Plumworasawat S, Bruminhent J |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-09-01
|
Series: | Infection and Drug Resistance |
Subjects: | |
Online Access: | https://www.dovepress.com/combined-pulmonary-tuberculosis-with-pulmonary-and-pleural-cryptococco-peer-reviewed-fulltext-article-IDR |
Similar Items
-
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
by: Srdan Verstovsek, et al.
Published: (2023-07-01) -
Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
by: Moshe Talpaz, et al.
Published: (2018-08-01) -
Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis
by: Novella Pugliese, et al.
Published: (2019-06-01) -
Tuberculosis in Patients with Primary Myelofibrosis During Ruxolitinib Therapy: Case Series and Literature Review
by: Peng Y, et al.
Published: (2020-09-01) -
Pleural cryptococcosis diagnosed by pleural biopsy in an immunocompromised patient: a case report
by: Hongxia Jia, et al.
Published: (2023-10-01)